SCHEMBL24257801

SCHEMBL24257801

CCOC(=O)CNC(=O)c1ncc(-c2cn(-c3ccc(F)cc3)nc2C)c(C)c1OO

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.38
TP53 P04637 2/20 0.37
MAPT P10636 1/20 0.37
KDM4E B2RXH2 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
EGLN1 Q9GZT9 3/20 0.35
VEGFA P15692 1/20 0.35
FLT1 P17948 1/20 0.35
EGLN3 Q9H6Z9 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26260146 0.91 RAB9A (0.43) RAB9ANPC1LMNAALDH1A1HPGD
SCHEMBL24257826 0.90 KDM4E (0.41) RAB9ALMNAALDH1A1HPGDKDM4E
SCHEMBL24257825 0.82 GAA (0.41) RAB9AALDH1A1HPGDKDM4EPOLB
SCHEMBL24257606 0.78 EGLN1 (0.48) RAB9ANPC1LMNAEGLN1VEGFA
SCHEMBL24257724 0.75 RIPK2 (0.39) RAB9ANPC1LMNAALDH1A1HPGD
SCHEMBL24257767 0.75 NPC1 (0.41) RAB9ANPC1LMNAALDH1A1HPGD
SCHEMBL24257796 0.74 EGLN1 (0.47) RAB9ANPC1LMNAALDH1A1HPGD
SCHEMBL24257782 0.71 EGLN1 (0.42) NPC1LMNAALDH1A1HPGDMAPT
SCHEMBL30454061 0.69 ALDH1A1 (0.43) RAB9ANPC1LMNAALDH1A1HPGD
SCHEMBL24257741 0.69 SMN1; SMN2 (0.39) RAB9ANPC1LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 RAB9A 739/4885NPC1 4011/4885LMNA 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.